These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15472342)

  • 1. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus.
    Lindström A; Odeberg J; Albert J
    J Clin Microbiol; 2004 Oct; 42(10):4788-95. PubMed ID: 15472342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N; Ichida T; Aoyagi Y; Kitajima I
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine.
    Xu G; You Q; Pickerill S; Zhong H; Wang H; Shi J; Luo Y; You P; Kong H; Lu F; Hu L
    J Med Virol; 2010 Jul; 82(7):1143-9. PubMed ID: 20513076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
    Luo Q; Zhong Y; Yang Y; Xiong Q; Hu Z; Lu W; Huang P; Zhang N
    J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR.
    Punia P; Cane P; Teo CG; Saunders N
    J Hepatol; 2004 Jun; 40(6):986-92. PubMed ID: 15158340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
    Alvarado-Esquivel C; de la Ascensión Carrera-Gracia M; Conde-González CJ; Juárez-Figueroa L; Ruiz-Maya L; Aguilar-Benavides S; Torres-Valenzuela A; Sablon E
    J Antimicrob Chemother; 2006 Feb; 57(2):221-3. PubMed ID: 16373428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
    Pichkovskaia VA; Fevraleva IS; Ibragimova MM; Solov'eva TI; Drel' PE; Sudarikov AB
    Mol Gen Mikrobiol Virusol; 2004; (1):27-9. PubMed ID: 15025001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural YMDD mutations of hepatitis B virus in Western China.
    Zhao J; Guo Y; Yan Z; Liang P; Zhang J; Liu Y
    Scand J Infect Dis; 2012 Jan; 44(1):44-7. PubMed ID: 21851334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.